Luyan Pharma Co., Ltd. (002788.SZ)
Luyan Pharma, a medical distributor listed on the Shenzhen Stock Exchange, experienced a sharp intraday decline on 31 December 2025. The share price fell to 21.18 CNY, the lowest level of the trading day, after a 1‑minute straight down‑limit. Trading volume exceeded 13 billion CNY and the turnover rate surpassed 15 %.
Market Context
- Sector Performance The Fujian free‑trade zone concept sector, of which Luyan Pharma is a constituent, declined 0.84 % on the day, marking one of the largest losses among concept groups. Net outflows from the sector reached 1.936 billion CNY, with eight stocks recording net outflows over 100 million CNY.
- Index Movements The Shanghai Composite Index edged down 0.07 %, the Shenzhen Component Index fell 0.67 %, and the ChiNext Index dropped 1.1 %.
- Sector Winners In contrast, the AI‑applications, commercial aerospace, and robotics concepts posted gains, with several stocks hitting consecutive limits or experiencing new‑stock surges.
Luyan Pharma’s Recent Performance
| Metric | Value |
|---|---|
| Close price (2025‑12‑30) | 21.18 CNY |
| 52‑week high (2025‑12‑30) | 24.35 CNY |
| 52‑week low (2025‑04‑08) | 7.23 CNY |
| Market cap | 8.23 billion CNY |
| P/E ratio | 26.48 |
| Shareholder count (as of 30 Sep 2025) | 22,700 |
The company’s shares had risen more than 160 % year‑to‑date, with December alone delivering over 110 % gains and achieving a “five‑board” streak. The recent limit‑down event has drawn attention to the stock’s volatility.
Company Response
When contacted by investors, Luyan Pharma’s staff acknowledged that the observed price fluctuations were within normal bounds. The company confirmed that it maintains an internal research and development team focused on artificial‑intelligence (AI) medical technologies. Products in development include AI‑assisted diagnostic tools for electrocardiography and fetal monitoring, which have already obtained medical device registration and commenced channel sales. A larger AI‑based cardiac application is still in the research phase and has not yet entered commercial deployment.
Implications for Investors
- The intraday limit‑down indicates heightened short‑term risk for the stock, potentially driven by sector‑wide selling pressure and the company’s high valuation relative to peers.
- Despite the recent decline, the company’s 52‑week high and substantial market cap suggest that Luyan Pharma remains a significant player in the medical distribution sector.
- Continued investment in AI technologies may provide long‑term upside, but investors should monitor the progress of product commercialization and regulatory approvals.
Note: The information above is based solely on the provided financial data and news excerpts.
